デフォルト表紙
市場調査レポート
商品コード
390847

肺癌手術の世界市場:タイプ、製品、地域別の成長率、動向および予測(2020年~2025年)

Lung Cancer Surgery Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 110 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円
肺癌手術の世界市場:タイプ、製品、地域別の成長率、動向および予測(2020年~2025年)
出版日: 2020年06月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 110 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

肺癌手術市場は、2018年から2023年の予測期間中、約7%のCAGRを記録すると見込まれています。肺癌は、肺組織における無秩序な細胞増殖が特徴の致命的な肺腫瘍です。肺癌の解釈は、気管支鏡またはCTガイダンスを用いて行う生検によって確認します。肺癌手術は、肺癌組織の外科切除です。手術の種類は、腫瘍の大きさおよび肺内のその位置によります。

当レポートでは、世界の肺癌手術市場を調査し、全体的な市場動向、タイプ・製品・地域別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ポーターのファイブフォース分析
    • サプライヤーの交渉力
    • 消費者の交渉力
    • 新規参入の脅威
    • 代替製品とサービスの脅威
    • 業界内での競争

第6章 成長要因、阻害要因、機会、課題の分析(DROC)

  • 市場の成長要因
    • 肺癌発症率の上昇
    • 低侵襲手術の分野における技術的進歩
    • 大気汚染レベルの上昇
  • 市場の阻害要因
    • 効果的な代替治療
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • タイプ別
    • 部分切除術
    • 肺葉切除術
    • 肺切除
    • スリーブ切除術
  • 製品別
    • 外科装置
    • モニター装置
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Accuray
  • Ethicon
  • GE Healthcare
  • Johnson & Johnson
  • オリンパス
  • Richard Wolf
  • Siemens Healthcare
  • その他

第10章 市場の将来展望

目次
Product Code: 55305

Rising air pollution and people getting affected by it are one of the prime factors responsible for the growth of the market for lung cancer surgery. As per an article by the Vital Strategies Environmental Health Division staff, 2018, while most of the 4.2 million premature deaths linked to air pollution are due to heart disease and strokes, around 1.7 million deaths are from lung cancer and other respiratory diseases globally. According to the WHO database, levels of ultra-fine particles of less than 2.5 microns are highest in India, which has 16 of the world's 30 most polluted cities. Thus, a rise in air pollution is, primarily, driving the lung cancer rate, and hence the studied market is expected to be impacted.

Key Market Trends

Segmentectomy is Expected to Witness High Growth

With the growing prevalence of lung cancer and technological development, the therapy line has also been improved and people can start taking treatment from the early stage, these factors are expected to further boost the growth of the lung cancer surgery market.

Segmentectomy is a common surgical treatment that can be an option to treat non-small cell lung cancer (NSCLC). It is mostly recommended over lobectomy if the patient already has a highly reduced lung reserve. Although lung segmentectomy has always been popular for resection of supportive lesions and nonmalignant masses, most of the time it is recommended for very early lung cancer.

The growing popularity of this technique is because of better outcomes, less pain, and shorter recovery than traditional surgical techniques. Segmentectomy procedure has a good success rate for removing localized tumors and cancers with higher survival rates, with the retention of organ functions up to a certain degree and these advantages are anticipated to fuel the studied market growth.

However, there are some risks associated with segmentectomy arising from general anesthesia, which raises the chances of excessive bleeding, blood clot formation, pneumonia, and infection of the surgical wound.

North America is Expected to Dominate the Market

As per the American Cancer Society's estimation, the new cases of lung cancer in the United States for 2018 were around 234,030, and about 154,050 deaths were expected due to lung cancer. In the United States, lung cancer survival has been improved and the incidence of localized lung cancer has increased.

According to the American Lung Association (2018), approximately 541,000 Americans living today have been diagnosed with lung cancer at some point in their lives. The majority of lung cancer patients have been diagnosed within the last five years. Each year, around tens of thousands of people, are cured of non-small cell lung cancer (NSCLC) in the United States. Lung cancer is mostly a disease of the elderly. This indicates the burden of lung cancer in this country and this is resulting in the growth of the market studied as there is a high demand for cancer treatment in the United States.

Competitive Landscape

The lung cancer surgery market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence, by introducing new products at cheaper prices.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Lung Cancer
    • 4.2.2 Technological Advancements in the Field of Minimally Invasive Surgeries
    • 4.2.3 Rise in the Level of Air Pollution
  • 4.3 Market Restraints
    • 4.3.1 Effective Alternative Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Thoracotomy
      • 5.1.1.1 Lobectomy
      • 5.1.1.2 Sleeve Resection
      • 5.1.1.3 Segmentectomy
      • 5.1.1.4 Pneumonectomy
    • 5.1.2 Minimally Invasive Surgeries
  • 5.2 By Product
    • 5.2.1 Surgical Devices
    • 5.2.2 Monitoring Devices
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Accuray Incorporated
    • 6.1.2 GE Healthcare
    • 6.1.3 Johnson & Johnson
    • 6.1.4 Olympus Corporation
    • 6.1.5 Richard Wolf GmbH
    • 6.1.6 Siemens Healthineers AG
    • 6.1.7 AngioDynamics Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS